SmallCap Trading Techniques

[I Like Bottom Fishing]

VDTI News VitalCare Updates Shareholders on Company Developm...
Thursday, May 22, 2008 9:05 AM

From:
"[e-mail]" <[e-mail]>
View contact details

Scottrade.com
This email is compliments of Scottrade.com
If you would like to modify or suspend this alert, please login to your Scottrade account and navigate to the "Alerts" page under the "My Account" tab.


News for 'VDTI' - (VitalCare Updates Shareholders on Company Developments Company Update)


CARSON CITY, Nev., May 22, 2008 (BUSINESS WIRE) -- VitalCare Diabetes Treatment
Centers, Inc. (Pink Sheets:VDTI), in an ongoing effort of updating shareholders
and continued public disclosure, is pleased to announce the following
accomplishments to date:

1. The Company has retained an SEC qualified auditing firm, Corso & Company, to
begin auditing its financials in an effort to initiate the steps to apply for
listing on the OTCBB, to finalize market maker representation, and to register
its securities and become a fully reporting company.

2. The Board of Directors passed a resolution to reduce the total authorized
shares of common stock from two billion (2,000,000,000) to two hundred fifty
million (250,000,000) shares.

3. The Company announced that the FDA approval (called allowance to market)
exists for the micro-dose pulsatile insulin infusion pump, used exclusively by
all licensed healthcare specialists, at all VitalCare Diabetes Treatment Centers
and affiliate locations who are certified to perform Intracellular Activation
Therapy (iCAT) treatment for Type 1 and Type 2 diabetes.

4. The Company completed an acquisition of the Inpulse Center of Scottsdale, AZ,
an operational diabetes clinic currently treating patients with Type 1 and Type
2 diabetes using the iCAT Therapy protocol.

5. The Company is pursuing its Midwest expansion strategy by executing Letters
of Intent for two locations in the state of Indiana, in affiliation with
Certified Wound Care Centers of Indiana and an agreement with South Valley
Inpulse Center, LLC, an existing Diabetes Treatment Center in Draper, Utah. The
centers will be administering the iCAT Treatment for secondary medical
complications of Type 1 and Type 2 diabetes patients.

6. The Company is now offering additional licenses in select markets to
qualified physicians and healthcare providers to establish affiliate locations
under a "sub-licensing" agreement for VitalCare Diabetes Treatment Centers.

7. The Company has recruited Tristan V. Voth-Stonger, MD as Executive Vice
President and Chief Medical Officer. Dr. Voth-Stonger is a Board Certified
Plastic and Reconstructive Surgeon who specializes in reconstructive surgery and
has extensive experience in treating difficult to heal wounds at his wound care
center locations. We believe that his experience in the area of wound care
management and incorporating the iCAT Therapy protocol will enhance the patient
outcomes of planned Diabetes Treatment Centers as well as enable the Company to
market directly to the medical community, physician to physician.

8. The Company has begun a special "Ask the Doctor" talk radio programming
schedule, featuring Marc Rose, MD, President of the Company, to educate the
public on the services provided by VitalCare Diabetes Treatment Centers and
affiliates. Each week, Dr. Marc Rose is interviewed on a local or nationally
syndicated radio talk show about iCAT Therapy and its benefits. The first
completed "Ask the Doctor" radio program was on the Topic: "FDA Approved
Diabetes Breakthrough" and was live on WOCA-AM 1370 out of Gainesville-Ocala, FL
which occurred on Wednesday, May 28, 2008 at 8:00am PST/11:00am EST, hosted by
Larry Whitler and Robin MacBlane; website www.woca.com.

About VitalCare Diabetes Treatment Centers, Inc.

VitalCare Diabetes Treatment Centers, Inc. is a company specializing in
providing Administrative, Marketing, Business Development, Strategic Planning,
Clinical Oversight and Clinical Management Services to the Diabetes Healthcare
Sector, with an emphasis in bringing "Cutting Edge" medical devices and
healthcare services direct to consumers, focusing on an emerging FDA approved,
US and European Patented technology and treatment intervention for treating Type
1 and Type 2 Diabetes known as "Intracellular Activation Therapy (iCAT)." The
World Health Organization (WHO) estimates that more than 180 million people
worldwide have diabetes. This number is likely to more than double by 2030 with
diabetes related deaths projected to increase by more than 50% in the next 10
years without urgent action. The US Center for Disease Control 2005 National
Diabetes Fact Sheet reports the total prevalence of Diabetes in the US for all
ages is 20.8 million of which 14.6 million are diagnosed and 6.2 million are
undiagnosed.

Safe Harbor Statement: Forward-looking statements in this release with respect
to VitalCare Diabetes Treatment Centers, Inc.'s business, financial condition
and results of operations, as well as matters of timing and the prospective
terms of the transaction described are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
VitalCare Diabetes Treatment Centers, Inc.'s control with respect to market
acceptance of their technology and/or products, whether financing will be
available, the effect of the application of acquisition accounting policies as
well as certain other risk factors which are and may be detailed from time to
time in VitalCare's filings with the Securities and Exchange Commission.

SOURCE: VitalCare Diabetes Treatment Centers, Inc.




CONTACT: VitalCare Diabetes Treatment Centers, Inc.Jimmy McDougaldInvestor Relations:1-877-NO-DIABETESFax: [e-mail]




Copyright Business Wire 2008

-0-




KEYWORD: United States

North America

Nevada

INDUSTRY KEYWORD: Health

Hospitals

Medical Devices

Diabetes

FDA

SUBJECT CODE: Economic News/Analysis

Source: Comtext Market News
Go to Previous message | Go to Next message | Back to Messages
ASCII (ASCII)Greek (ISO-8859-7)Greek (Windows-1253)Latin-10 (ISO-8859-16)Latin-3 (ISO-8859-3)Latin-6 (ISO-8859-10)Latin-7 (ISO-8859-13)Latin-8 (ISO-8859-14)Latin-9 (ISO-8859-15)W. European (850)W. European (CP858)W. European (HPROMAN8)W. European (MACROMAN8)W. European (Windows-1252)Armenia (ARMSCII-8)Baltic Rim (ISO-8859-4)Baltic Rim (WINDOWS-1257)Cyrillic (866)Cyrillic (ISO-8859-5)Cyrillic (KOI8-R)Cyrillic (KOI8-RU)Cyrillic (KOI8-T)Cyrillic (KOI8-U)Cyrillic (WINDOWS-1251)Latin-2 (852)Latin-2 (ISO-8859-2)Latin-2 (WINDOWS-1250)Turkish (ISO-8859-9)Turkish (WINDOWS-1254)Arabic (ISO-8859-6, ASMO-708)Arabic (WINDOWS-1256)Hebrew (856)Hebrew (862)Hebrew (WINDOWS-1255)Chinese Simplified (GB-2312-80)Chinese Simplified (GB18030)Chinese Simplified (HZ-GB-2312)Chinese Simplified (ISO-2022-CN)Chinese Simplified (WINDOWS-936)Chinese Trad.-Hong Kong (BIG5-HKSCS)Chinese Traditional (BIG5)Chinese Traditional (EUC-TW)Japanese (SHIFT_JIS)Japanese (EUC-JP)Japanese (ISO-2022-JP)Korean (ISO-2022-KR)Korean (EUC-KR)Thai (TIS-620-2533)Thai (WINDOWS-874)Vietnamese (TCVN-5712)Vietnamese (VISCII)Vietnamese (WINDOWS-1258)Unicode (UTF-7)Unicode (UTF-8)Unicode (UTF-16)Unicode (UTF-32)
| Full Headers
Search Mail